Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$28.30 USD

28.30
37,883,682

-0.22 (-0.77%)

Updated Oct 31, 2024 04:00 PM ET

After-Market: $28.34 +0.04 (0.14%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 23% (53 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More

by Zacks Equity Research

Let's look at the five biotech/pharma companies, slated to release quarterly results on May 3.

How Will Pfizer's (PFE) Key Drugs Perform in Q1 Earnings?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Eliquis (alliance revenue), Xtandi and Inlyta, and revenues from the COVID-19 products are likely to have driven sales in the first quarter.

Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?

by Zacks Equity Research

Sector ETF report for XLV

Bristol-Myers (BMY) Q1 Earnings Beat Estimates, Guidance Down

by Zacks Equity Research

Bristol-Myers (BMY) earnings beat estimates in the first quarter of 2022. Sales jump year over year on the back of Eliquis and new products.

Pfizer (PFE) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the first quarter.

Kinjel Shah headshot

Pharma Stock Roundup: Q1 Earnings of LLY, MRK & NVS, FDA Updates for AZN & PFE

by Kinjel Shah

Eli Lilly (LLY), Merck (MRK), Novartis (NVS) and others announce Q1 results. FDA updates for AstraZeneca (AZN) and Pfizer (PFE) grab headlines in the pharma space.

AbbVie (ABBV) Tops Q1 Earnings Estimates

by Zacks Equity Research

AbbVie (ABBV) delivered earnings and revenue surprises of 0.32% and 0.09%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Merck (MRK) delivered earnings and revenue surprises of 18.23% and 5.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Innoviva (INVA) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Innoviva (INVA) delivered earnings and revenue surprises of 5% and 76.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Glaxo's (GSK) Q1 Earnings Top, Xevudy Adds $1.7B in Sales

by Zacks Equity Research

Glaxo's (GSK) revenues benefit from the strong growth in sales across all categories along with additional sales from its COVID-19 antibody drug, Xevudy.

Should You Invest in the Vanguard Health Care ETF (VHT)?

by Zacks Equity Research

Sector ETF report for VHT

Pfizer (PFE) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Pfizer (PFE) closed at $49.03, marking a +0.16% move from the previous day.

Pfizer (PFE) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sweta Killa headshot

Healthcare ETFs in Focus Ahead of Q1 Earnings

by Sweta Killa

The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.

Novavax (NVAX) Starts COVID-19 Booster Study in Adolescents

by Zacks Equity Research

Novavax's (NVAX) begins administering a third/booster dose of its COVID-19 vaccine in adolescents aged between 12 years and 17 years in a pivotal late-stage study.

Novavax (NVAX) Posts Upbeat Data on COVID/Flu Combo Jab Study

by Zacks Equity Research

Results from Novavax's (NVAX) phase I/II study, which is evaluating a combination of its COVID-19 vaccine and the seasonal influenza vaccine candidate, demonstrate the combo vaccine's feasibility.

Pfizer (PFE) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Pfizer (PFE) closed at $49.75, marking a -0.86% move from the previous day.

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Moderna (MRNA) Posts Upbeat Data on Bivalent COVID Booster Jab

by Zacks Equity Research

Moderna's (MRNA) bivalent COVID booster candidate creates superior neutralizing antibodies compared to its currently authorized COVID vaccine mRNA-1273's booster dose against all variants of concern.

Exelixis (EXEL) Outperforms Industry YTD: What Lies Ahead?

by Zacks Equity Research

Exelixis (EXEL) gains 25% in the year so far on strong performance of Cabometyx and encouraging pipeline progress.

Pfizer (PFE), BioNTech (BNTX) COVID Booster Effective in Young Kids

by Zacks Equity Research

A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.

Merck's (MRK) Pneumococcal Jab Gets FDA's Breakthrough Tag

by Zacks Equity Research

The FDA grants Breakthrough Therapy designation to Merck's (MRK) vaccine candidate, V116, for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults.

Novavax (NVAX) COVID Jab Gets Nod for Use in Switzerland

by Zacks Equity Research

Novavax's (NVAX) Nuvaxovid is the first protein COVID-19 vaccine authorized for use in Switzerland. The stock price rises following the announcement.

Halozyme (HALO) to Acquire Antares for Auto Injector Platform

by Zacks Equity Research

Halozyme (HALO) is set to acquire Antares for $960 million by June. The acquisition will add Antares' auto injector platform to Halozyme's portfolio and complement its promising ENHANZE technology.

The Zacks Analyst Blog Highlights Pfizer, Charles Schwab, Vale, Citigroup, and Palo Alto Networks

by Zacks Equity Research

Pfizer, Charles Schwab, Vale, Citigroup, and Palo Alto Networks are part of the Top Analyst Blog.